DUX4 and facioscapulohumeral muscular dystrophy: The subcutaneous administration route and two-week dosing interval of MT-DUX4-ASO will be quite feasible and convenient for clinical use by FSHD patients who require life-long treatment because DUX4 expression occurs intermittently and randomly throughout their life in only a subset of myofibers at a time.